Premium
The physiologic disposition of dichloromethotrexate‐CI 36 in man
Author(s) -
Davidson Jack D.,
Oliverio Vincent T.
Publication year - 1965
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196563321
Subject(s) - urinary system , feces , methotrexate , metabolism , urine , excretion , medicine , pharmacology , pharmacokinetics , endocrinology , chemistry , biology , paleontology
Pharmacologic studies were made of the urinary and fecal excretion, blood levels, metabolism, and plasma binding of 3′,5′‐dichloromethotrexate (DCM), with a radioactive chlorine label, in patients with cancer. DCM was found to differ significantly from methotrexante in that half of both oral and intravenous doses are eliminated via the bile and feces. Approximately one third of a dose is also metabolically inactivated. The existence of these alternates to the urinary pathway of elimination suggests that DCM may be a less toxic antifolic agent than methotrexate in patients with impaired renal funcion.